AbCellera Biologics (ABCL) to Release Earnings on Tuesday

AbCellera Biologics (NASDAQ:ABCL) will likely be announcing its earnings results after the market closes on Tuesday, February 18th. Analysts expect the company to announce earnings of ($0.15) per share for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link.

AbCellera Biologics Stock Down 2.6 %

Shares of NASDAQ ABCL opened at $3.02 on Tuesday. AbCellera Biologics has a 52 week low of $2.34 and a 52 week high of $5.46. The firm has a market cap of $892.02 million, a P/E ratio of -4.95 and a beta of 0.42. The business’s 50 day moving average price is $3.04 and its 200 day moving average price is $2.83.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on ABCL. KeyCorp cut their price objective on shares of AbCellera Biologics from $5.00 to $4.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 8th. Benchmark reiterated a “hold” rating on shares of AbCellera Biologics in a research note on Tuesday, November 5th. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $12.00 price objective (down previously from $14.00) on shares of AbCellera Biologics in a report on Tuesday, November 5th.

AbCellera Biologics Company Profile

AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company’s preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.